The World Market for Cardiovascular Diagnostics (Markets for ECG, Imaging, Cardiac POC, Contrast Agents and Cardiac Markers)

This report, The World Market for Cardiovascular Diagnostics, provides the reader with an overview of the global cardiac diagnostics industry and the trends driving growth. Segments within the cardiac diagnostic market include:

• Electrocardiography including ECG testing, stress testing, Holter monitoring, event monitoring and implantable loop.
• Cardiac imaging including non-invasive X-Ray, MRI, CT, ultrasound, and nuclear cardiography; and invasive /cardiac catheterization/angiography, intravascular ultrasound, optical coherence technology and electrophysiology.
• Cardiac point-of-care including cholesterol testing and coagulation testing
• Cardiac markers
• Cardiac contrast agents and radiopharmaceuticals

For each of these segments, market size and forecast, along with compound annual growth rate is provided. Also included in the report are statistics influencing the industry, incidence of cardiac and related diseases worldwide, demographics, life expectancy, and company strategies. Information is presented as a global market. A market summary includes a total market analysis. Also included is a competitive analysis of leading cardiac diagnostic providers.

Economic conditions in several markets within the global cardiac diagnostics market remained challenging in 2012. Demand for cardiovascular diagnostics slowed during the historical period due to a weakened global economy, cost cutting measures and healthcare reform issues. However, demographics worldwide and an aging world society remain primary factors in growth. By 2020, 16 percent of the US population will be over the age of 65, up from 13% in 2010. People are also living longer, needing more health care, further fueling the market. In 1980, the US life expectancy at birth was 74 years, today the average American lives to be 78 years old.

The global cardiac diagnostic industry is a diverse and highly competitive market. It is anticipated that provider demand for cardiac diagnostic products and services will continue to rise providing opportunities for both existing market participants and emerging market participants. Manufacturers should look for ways to distinguish themselves in the marketplace by keeping abreast of key market drivers, restraints, and trends that are affecting the market and the economy as a whole. More than ever before, manufacturers are facing survival challenges in today’s marketplace while the need for innovative and safe products continues to grow.

Companies profiled in this report include:

• Abbott Diagnostics
• Acusphere
• Alere
• Analogic Corp
• Bayer Healthcare
• Bracco SpA
• Cardinal Health
• CardioDX
• C.R. Bard
• Danaher Corporation
• dpiX
• FluoroPharma Medical
• GE Healthcare
• Hitachi Medical Systems
• Johnson & Johnson
• King Pharmaceuticals
• Lantheus Medical Imaging
• LipScience
• Medison America
• Molecular Insight Pharmaceuticals
• Nanosphere
• PerkinElmer
• Philips Healthcare
• Roche Diagnostics
• Shimadzu Corp
• Siemens Medical Solutions
• St Jude Medical
• Terumo Medical
• TomTec Imaging Systems
• Toshiba
• Trixell
• Vascular Solutions
• Vermillion
• Volcano

Some of these companies are high stakes players in the market and control considerable market share while others are small or niche players that provide a valuable product to the global cardiac diagnostic arena. All are equally important to the market as a whole.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with more than 21 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. Revenues represent sales of diagnostics that pertain to the cardiovascular arena. The base year for data was 2012. Historical data was provided for the years 2010 and 2011, with forecast data provided for 2012 through 2017. Compound annual growth rates (CAGRs) are provided for the 2010-2012 and 2012-2017 periods for each region and/or segment covered. Competitive analysis is provided for the year 2012. The forecasted market analysis for 2012-2017 was largely based on demographic trends, new developments, company performance trends, merger and acquisitions, and national expansion.